Abstract: The present invention relates to a method for treating at least a surface of a substrate containing labile hydrogen atoms to confer to it cytotoxic properties or cell-adhesion properties, characterized in that it comprises at least a step consisting of exposing, within a liquid medium, said substrate or a surface thereof with at least a copolymer, said copolymer containing at least a monomer unit of type A including at least a reactive site able to attach to said substrate or said surface by covalent bonds and at least a monomer unit of type B including at least one molecule able to confer antimicrobial, antiviricidal and/or antifungicidal or cell-adhesion properties to said substrate or said surface, said step being carried out in efficient conditions to promote the covalent grafting of said copolymer to said substrate or a surface thereof.

Abstract: A method and catalytic systems for treating a gas to reduce nitrogen oxide emissions are disclosed. The catalytic systems can include a catalytic composition which comprises an active phase on a support. The active phase is based on rhodium in the form RHx+ and at least another element selected among palladium and platinum and the support is based on cerium oxide and zirconium oxide. Gases capable of being treated by the method and the catalytic systems include in particular those derived from gas turbines, from gas-fired or coal-fired stream plant boilers, or from internal combustion engines.

Abstract: This invention concerns compositions of chondrocytic cells, notably human ones, and the methods for preparing and using them. More specifically, the invention describes the production of autologous human chondrocyte suspensions, employing recombinant enzymes and/or media that are compatible with pharmaceutical use. The invention also describes methods and compositions for freezing chondrocytes, notably in the absence of DMSO. The chondrocytes which are produced can be used in vivo to restore affected cartilaginous structures, such as in post-traumatic cartilaginous defects or dissecting osteochondrite of the knee or, more generally, for treating and repairing clinically significant defects in cartilage, notably in joint cartilage.